^
BIOMARKER:
ALK rearrangement
i
Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Entrez ID:
ALK rearrangement
NSCLC
crizotinib
Sensitive
:
A2
ALK rearrangement
NSCLC
alectinib
Sensitive
:
A2
ALK rearrangement
NSCLC
ALK inhibitor
Sensitive
:
A2
ALK rearrangement
NSCLC
ceritinib
Sensitive
:
A2
ALK rearrangement
NSCLC
lorlatinib
Sensitive
:
A2
ALK rearrangement
NSCLC
brigatinib
Sensitive
:
A2
ALK rearrangement
NSCLC
nivolumab
Sensitive
:
C2
ALK rearrangement
NSCLC
crizotinib + bevacizumab
Sensitive
:
C3
ALK rearrangement
LUAD
Tyrosine kinase inhibitor
Sensitive
:
C3
ALK rearrangement
NSCLC
PD-L1 inhibitor
Resistant
:
C3
ALK rearrangement
NSCLC
Tyrosine kinase inhibitor
Sensitive
:
C3
ALK rearrangement
NSCLC
Immunotherapy
Sensitive
:
C3
ALK rearrangement
NHL
ceritinib
Sensitive
:
C3
ALK rearrangement
NSCLC
IPI-504
Sensitive
:
C3
ALK rearrangement
NSCLC
ipilimumab
Sensitive
:
C3
ALK rearrangement
Lung Non-Small Cell Squamous Cancer
ALK inhibitor
Sensitive
:
C3
ALK rearrangement
RCC
crizotinib
Sensitive
:
C4
ALK rearrangement
Sarcoma
crizotinib
Sensitive
:
C4
ALK rearrangement
LUAD
crizotinib
Resistant
:
C4
ALK rearrangement
LUAD
bevacizumab
Sensitive
:
C4
ALK rearrangement
RCC
alectinib
Sensitive
:
C4
ALK rearrangement
Lung Cancer
BMS-722782
Sensitive
:
D
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our